Analysis for the optimal condition of the autologous platelet rich plasma therapy

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K09085
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56020:Orthopedics-related
• Research Institution: Jikei University School of Medicine
• Principal Investigator: Yoshida Mamoru 東京慈恵会医科大学, 医学部, 准教授 (10266702)
• Co-Investigator(Kenkyū-buntansha): 舟崎 裕記 東京慈恵会医科大学, 医学部, 教授 (70199412) ; 丸毛 啓史 東京慈恵会医科大学, 医学部, 教授 (70199925)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: Platelet-rich plasma / Platelet concentration / Leukocyte concentration / Enthesopathy / Tendinopathy / Sports injury

Outline of Final Research Achievements

In an animal model of tendinopathy, we determined if there was an optimal PRP platelet concentration. PRP at platelet concentrations of 50(P50), 75(P75), 100(P100) and 150×10000/μL(P150) or normal saline (control) was injected into the tendinopathy tendon. Activities in the P75 and P100 were significantly greater than in the P50, P150 and control. The numbers of microtears, laminations and apoptotic cells in tendons in the P75 and P100 were fewer than in the P50, P150 and control (Because of a few sample numbers, no statistical analysis was performed). These findings indicated that the optimal PRP platelet concentration was approximately a range of 75 to 100×10000/μL.

Free Research Field

PRP治療、スポーツ障害

Academic Significance and Societal Importance of the Research Achievements

これまでPRP治療の至適血小板濃度は不明であり、施設間や精製キット間で濃度は統一されておらず、異なる条件下での治療成績が論じられてきた。本研究により、至適条件が明らかとなり、今後は統一した条件でPRP治療が施行されることにより、本治療法の適応と限界が明確になり、それにより、治療効果の予測が容易になることから、PRP治療か手術治療かの治療方法の選択が適切に行われ、最短時間で治療を行うことが可能になり、実臨床に多大な貢献ができる。